Global JLABS Portfolio Overview - Johnson & Johnson Innovation

Global JLABS Portfolio Overview January 2018

1

Portfolio Navigation JLABS GENERAL INFORMATION:

WELCOME & PORTFOLIO …........... 4

GLOBAL REACH …........................ 5

CONTACTS …................................ 6

SEARCH PORTFOLIO BY: THERAPEUTIC AREA:

R&D STAGE:

PHARMA …............................... 12-15

OVERVIEW …............................... 21

MEDICAL DEVICES …............... 16-17

PHARMA ….............................. 22-23

CONSUMER …........................... 18-19

MEDICAL DEVICES …................... 24

CROSS-SECTOR …........................ 20

CONSUMER ….............................. 25

COMMUNITY @ JLABS …............ 7-8

INVESTOR HUB ….......................... 9

JPALS …..................................... 10

QUICKFIRE CHALLENGES:

FUNDING STAGE …........................................….............................…................................ 26-29

OVERVIEW …................................ 31

CHALLENGE DETAILS ….......... 32-37

2

General Information Locations, Leadership, and Community

3

Portfolio Navigation

JLABS Companies (n=330) Welcome to the January 2018 update for the JLABS Portfolio of Companies. This interactive guide provides a snapshot of how JLABS companies and community are moving the future of healthcare closer to patients. As JLABS grows across nine locations in the US, Canada and Asia, our portfolio has diversified to include companies spanning a broad spectrum of development stage, funding, and clinical area focus. In parallel, the JLABS community of programming, embedded resources, partnered investors, expert relationships, and regional events continues to expand and evolve in order to support the changing needs of early stage innovation. We invite you to learn more and look forward to making a connection!

Melinda Richter

Below is a quick snapshot of how current JLABS portfolio companies are represented across healthcare sectors. Click a sector below to view the JLABS portfolio companies by sector

210

72

PHARMACEUTICALS

MEDICAL DEVICES

48

46

CONSUMER

QUICKFIRE CHALLENGE WINNERS

Global Head, Johnson & Johnson Innovation, JLABS

54 CROSS-SECTOR

4

Portfolio Table ofNavigation Contents

JLABS Global Reach TORONTO JLABS @ TORONTO September 2015

LOWELL, MASS JLABS @ M2D2 December 2016

JLABS @ Toronto QuickFire Challenge

JLABS @ M2D2 QuickFire Challenge

Artificial Intelligence for Drug Discovery QuickFire Challenge

ALBERTA JPOD

JPOD

QUICKFIRE CHALLENGES

Next-Gen Baby Box QuickFire Challenge Finland

Seoul Innovation QuickFire Challenge

Bugs, Drugs, & Beyond QuickFire Challenge

SHANGHAI JLABS @ Shanghai Opening 2019

NYC JLABS @ NYC Opening Q2 2018

SOUTH SAN FRANCISCO JLABS @ SSF January 2013

Bugs, Drugs, & Beyond QuickFire Challenge

JLABS PARTNERSHIPS

JLABS @ LabCentral QuickFire Challenge

BAY AREA JLABS @ QB3 June 2015

JLABS @ SSF QuickFire Challenge

BOSTON JLABS @ LABCENTRAL June 2013

JLABS

JLABS @ NYC QuickFire Challenge

SAN DIEGO Flagship January 2012 JLABS San Diego QuickFire Challenge

HOUSTON JLABS @ TMC March 2016 JLABS @ TMC QuickFire Challenge Next-Gen Supply Chain QuickFire Challenge

Bugs, Drugs, & Beyond QuickFire Challenge CDI @ TMC QuickFire Challenge

Latin America QuickFire Challenge

GLOBAL FOCUS:

Singapore QuickFire Challenge – Metabolic Disease Innovation

Patient Adherence QuickFire Challenge The LabCoat of the Future Challenge Digital Beauty QuickFire Challenge

Advance Queensland Johnson & Johnson Innovation QuickFire Challenge

Advancing the Safe Use of Healthcare QuickFire Challenge World Without Disease QuickFire Challenge

5


Contacts Meet the Heads of our JLABS sites and QuickFire Challenges. They look forward to hearing from you. KARA BORTONE, Ph.D. San Diego | [email protected]

THOMAS LUBY, Ph.D. TMC | [email protected]

Kara has a background in biochemistry and structural biology and expertise in translating science research to a wide variety of audiences including the medical, lay and investor communities. Before joining JLABS in 2012, Kara spent 10 years in European biotech, first as an editor of the biochemistry journal FEBS Letters and later in investor relations/communications with NASDAQ listed Belgian biotech company Galapagos NV.

Tom trained in immunology and started his career in R&D focused on the development of immunotherapies for allergy, infectious disease and cancer at two successful start-up biotechs. He then transitioned to business development management roles with a focus on partnering and fund-raising for rare disease-focused companies. He joined J&J as a New Venture Lead at the Boston Innovation Center before transitioning to his current role at JLABS @ TMC.

KATHERINE MERTON, Ph.D. NYC, LabCentral, M2D2 | [email protected]

LESLEY STOLZ, Ph.D. SSF & QB3 | [email protected]

Kate has cross-functional expertise in Pharma R&D and on the commercial side of healthcare having worked in medical affairs, marketing and health outcomes. Kate has developed a range of skill sets that allow her to provide insight on the end-to-end development of interventions to meet patient needs including the role of health technology.

Lesley Stolz has deep expertise in business and corporate development including business strategy, deal definition, negotiation and execution. Trained as a scientist, she also has strong operations experience from 18 years as an executive in small therapeutic companies working on innovative approaches to bring new solutions to patients.

KULDEEP NEOTE, Ph.D. Toronto | [email protected]

ERIKA KULA QuickFire Challenges | [email protected]

Kuldeep has expertise in the areas of immunology, inflammation and oncology and has deep expertise in drug discovery. Throughout his career he has looked at creative, scientific and business development collaborative and partnering opportunities that have resulted in tangible clinical translation of new scientific discoveries.

Erika’s career has been focused on assisting early stage companies to successfully commercialize their science and technology solutions. Trained in neuroscience and business, she has worked with major corporations, government entities and early stage companies for over a decade. She joined J&J in 2017 after starting her own consulting firm in 2014.

6


Community @ JLABS

At JLABS, we build a community of relationships and experiences for our companies, partners, investors and stakeholders. CEO Summit and Inside Scoop are two new events focused on connecting our global community. The inaugural JLABS CEO Summit took place on October 18-19, 2017 in La Jolla, CA. The two-day program included a JPAL Mentor Day where JLABS CEOs connected with experts from across J&J and a day-long CEO Summit featuring talks from J&J executives, JLABS CEOs, investors and industry thought leaders. The day-long program concluded with the 5 Year Anniversary of JLABS networking event featuring a “Healthcare Visionaries” panel and networking reception.

CEO SUMMIT PARTICIPANTS

254 5 YEAR ANNIVERSARY ATTENDEES

BREAKDOWN

126

93

26

JLABS Companies

J&J Attendees

Investors

33

26

Total Speakers

Total Speaking Programs

550 7

Community @ JLABS


What: Companies new to JLABS quick-pitch to a live audience of industry executives, investors, entrepreneurs and community partners Where: All JLABS Locations + Select Innovation Centers + Enterprise Wide JNJ Sites When: The next Inside Scoop will be held March 7, 2018

Register: https://jlabs-portfolioshowcasefeb2018.eventbrite.com/

JLABS INSIDE SCOOP 8

Investor Hub


If you are an investor and interested in learning more about the Investor Hub, please contact one of our JLABS Site Heads.

The Future – Powered by JJDC With the commitment and backing of JJDC, Investor Hubs are launching across all JLABS locations. The power of JJDC is bringing along investors of all types and focuses – unlocking unlimited potential for JLABS portfolio companies. We started with one in Toronto and now have more than 30 investor groups across North America! JJDC will be a physical presence, fostering mentorship and investment for JLABS portfolio companies, bringing along an extensive network of syndicate investors.

JJDC is the strategic venture arm of Johnson & Johnson, they invest across all sectors and at all stages, from seed-level start-ups to Series B and beyond.

9


JPALS Experts from across Johnson & Johnson commit their time and knowledge to support JLABS companies through the JPALS program. DePuy Orthopedics Suzanne Thompson, Research Fellow – Preclinical COE Emir Osmanagic, Director of Enabling Technologies Hassan Serhan, Distinguished Engineering Fellow

Ethicon Bethany Grant, R&D Director, Advanced Innovation Charles Bridges, Therapeutic Area Expert, NBD External Innovation Brian Johnson, Sr. Director, Advanced Innovation Gerry Llanos, Research Fellow

J&J Consumer Kate Luedtke, Associate Director Stefanie Dhanda, Sr. Director, Consumer Scientific Innovation Gabriela Oana Cula, Research Associate Director Stephanie Robertson, Sr. Director, Consumer Science Innovation Elizabeth Wu, Sr. Analyst, Consumer Scientific Innovation Christopher (Chris) Flores, Sr. Director, R&D, Consumer Gerry McNally, Research VP Global OTC Technology

J&J Enterprise Maureen Boudreau, Director, Healthcare Technology Center Gloria Candelario Hossri, IT Director, Healthcare Technology Services John Minardi, ITAS, Sr. Director, Health Technology

Janssen Yiu-Lian Fong, External Innovation Lead EMEA – Dx Janey Shin, Director, Real World Evidence Suzanne Edavettal, Principal Scientist, Discovery Emma Huang, Associate Scientific Director, CS-Computational Bio Tara Mirzadegan, Sr. Director Sheri Moores, Associate Director, US Oncology Biology Ulrike Philippar, Scientific Director Irene Rombel, Director, Strategy Innovation and New Ventures Sandra Snook, Sr. Scientific Director Katherine Tsokas, Regulatory Head of Regenerative Medicine & Advanced Therapy Ricardo Attar, Sr. Director, US Biology Oncology Dash Dhanak, Global Head, Discovery Sciences Michael Elliott, Vice President, Immunology Scientific Innovation Francois Gaudet, Scientific Director, US Biology Oncology Sri Gopal, Sr. Director, Clinical Leader, Central Nervous System Jeff Infante, VP Early Development Paul Jackson, Scientific Director Sanjay Jalota, Sr. Director Michael Kelley, Sr. Scientific Director, PDS-PCD Team Nicola La Monica, Sr. Director, Infectious Disease Scientific Innovation Russell (Russ) Lingham, Scientific Director, JBIO Strategy Kevin Lumb, Global Head, Screening Michael Naso, Scientific Director Dave Pocalyko, Head of Translational Sciences Robert (Bob) Radinsky, VP, Oncology Scientific Innovation Tadimeti Rao, Scientific Director and Fellow Eric Schaeffer, Sr. Director, Scientific Innovation Neuroscience Siquan Sun, Associate Scientific Director Ron Swanson, Sr. Director, Discovery Science Dmitri Talantov, Sr. Director, Medical Affairs Peter Ten Holte, Associate Director, Business Office Integrator Jim Tobin, VP, Cardiovascular & Metabolic Scientific Innovation Jorge Vialard, Associate Scientific Director, BE Discovery Biology, Oncology Jay Wadia, Scientific Director Piet De Donker, Portfolio Integration Leader Paul Acton, Scientific Director & Fellow

Johnson & Johnson Innovation Tatyana Beldock, Sr. Director, New Ventures Jackie Benson, VP Immunology Sci Innovation Sylvaine Cases, VP Oncology Sci Innovation Kathy Connell, Sr. Director, New Ventures Marianne DeBacker, Vice President, Venture Investments Jennifer Hamilton, Sr. Director, New Ventures Beth Hill, Sr. Director, Platform Innovation Yelda Kaya, Sr. Director, Transactions Han Li, Partnership Management Widya Mulysasmita, Director, New Ventures Marian Nakada, VP, Venture Investments Erin Wahington, Sr. Manager, Transactions and BD Carolyne Zimmerman, Sr. Director, Transactions Ibraheem (Ib) Badejo, Sr. Director, Scout/New Ventures Jeff Calcagno, New Ventures Cris De Luca, Digital Health Lead Dana Deardorff, New Ventures, Medical Device Alexander Grunewald, Global Head Healthcare Innovation Strat Thomas (Gus) Gustafson, VP Science Innotion CVM Nicholas Mourlas, Sr. Director, New Ventures Kuldeep Neote, Sr. Director, Scout/New Ventures (D2) Guy Seabrook, VP, Neuroscience Innovation

JLABS Kara Bortone, Head, JLABS San Diego Katherine Merton, Head, JLABS @ NYC & Boston Kuldeep Neote, Head, JLABS @ Toronto Lesley Stolz, Head, JLABS California Tom Luby, Head, JLABS @ TMC

VISTAKON Hassan Chaouk, Sr. Principal Scientist Shivkumar Mahadevan, Research Fellow

10

Portfolio Overview

11


Pharmaceutical Companies (n=210) Click a therapeutic area below to view the corresponding profiles

NEUROSCIENCE

14 DX ENABLING TECHNOLOGIES

PULMONARY HYPERTENSION

Antibody Based Therapeutics

1

Microfluidics

1

Assay Measurement

1

Non-coding DNA

1

Biomarker

2

Pharmaceutical Manufacturing

1

Cell Tracking

2

Protein Therapeutics

1

Chronic Pain

3

Rare Disease

1

Diagnostics

1

Retina

HEALTH TECH

1

DNA Synthesis

5

RNA

14

Drug Discovery

1

Semi-synthetic Biologics

2

Drug Resistance

1

Vaccines

2

Exogenous Controlled/Therapeutics

1

3D Printing

4

Genomics

4

Health Tech

11

73

DIAGNOSTICS

CVM

3

1

3

IMMUNOLOGY

IDV

2

11

52

PLATFORM

21

ONCOLOGY

1

If you're interested in learning more about these companies on our website click here.

12


Pharmaceutical Companies (n=210) 11

CVM: Cardiovascular Disease:

Microbiome:

11

Immunology:

Alzheimer’s:

Pulmonary:

IBD:

21

Neuroscience:

Fibroses:

Rheumatoid Arthritis:

Medication Compliance:

Mood Disorders:

Nerve Regeneration:

Diabetes:

14

IDV: Hepatitis:

Chronic Pain:

Seizure:

Parkinson’s Disease:

Neuromodulation:

Liver + GI:

HPV:

Sickle Cell Disease:

Respiratory:

Anti-Fungal:

T-cell:

Other Area of Interest:

STEALTH Cystic Fibrosis:

2

DX Enabling Technologies: Biomarker:

1

Pulmonary Hypertension:

Drug Resistance:

Stem Cells:

Idiopathic Pulmonary Fibrosis: Vaccines:

Diagnostics:

3

Health Tech: Big Data:

1

Neuroscience:

Patient Monitoring:


13


Pharmaceutical Companies (n=210) Oncology

73

Heme Malignancies:

Immuno-oncology:

Antibody Based Therapeutics:

STEALTH

Discovery Platform:

Pain:

Chemotherapy Resistance:

Glioblastoma:

Solid Tumor:

STEALTH

Stem Cells:

Phenzyme

Macular Degeneration:

T cell:

Prostate:

STEALTH Transport Targets:

Renal:

Lung Cancer Initiative:

Microbiome: Proteome:


14


Pharmaceutical Companies (n=210) Platform Retina:

52 Chronic Pain:

Assay Measurement:

Biomarker:

Diagnostics:

Rare Disease:

STEALTH

Antibody Based Therapeutics:

Cell Tracking:

Health Tech:

Drug Discovery:

Pharmaceutical Manufacturing:

Non-coding DNA:

DNA Synthesis:

Microfluidics:

RNA:

Semi-synthetic Biologics:

STEALTH

Protein Therapeutics:

Drug Resistance:

STEALTH

Praedicare

Exogenous Controlled/Therapeutics:

Genomics:

STEALTH


15


Medical Devices Companies (n=72) Click a therapeutic area below to view the corresponding profiles

PLATFORM

VISION CARE

9 1

13

DIAGNOSTICS

LUNG CANCER INITIATIVE

7

21

DX TESTS/ASSAYS

DX ENABLING TECHNOLOGIES

12

1

HEALTH TECH

Drug Delivery

GENERAL SURGERY

6


16


Medical Devices Companies (n=72) Diagnostics: Breast:

Diabetes:

12

DX Enabling Technologies: DX Technology:

Neuroscience:

Cardiology:

13

General Surgery:

Stem cells: Diabetes/Obesity:

Dx Technology – Amplification Technologies:

Neuroscience:

DNA/RNA Detection:

Orthopedics: DNA/RNA Detection:

21

Cardiovascular:

Surgery:

Inflammation: Diabetes:

STEALTH Oncology:

Lung Cancer Initiative: Lung Cancer Initiative

Infectious Disease:

1

Platform:

1

Drug Delivery:

Injectables:

Nanoparticles:

Health Tech:

7

Big Data:

Vision Care:

DX Tests/assays: Infectious Disease:

Oncology

STEALTH

6

9

Vision Correction:

Sensor Technology:

Strategically Aligned: Patient Engagement: Manufacturing:

Macular Degeneration:

Social Media/eCommerce:

DX Platform:


17


Consumer Companies (n=48) Click a therapeutic area below to view the corresponding profiles

OTHER

1

WELL BEING & BEAUTY

19

2

HEALTH & HEALING

Pediatric

DX ENABLING TECHNOLOGIES

12

11

HEALTH TECH


18


Consumer Companies (n=48) Well-Being & Beauty:

19

Baby Care:

Sun Care:

DX Enabling Technologies: DX Technology:

Facial Skin Care:

Health & Healing: Compromised Skin Care:

Body Care:

2

Manufacturing:

Pediatric:

Oral Care:

12

Pain Care:

STEALTH

1

Other:

Dry Eye:

Digestive Health:

Pediatric:

Circulation Concepts Inc.

eCubed Designs

11

Health Tech: Big Data:

Patient Engagement:

Virtual/Augmented Reality:

Sensor Technology:


19

Primary sector

Cross-sector Companies CONSUMER | 9

Secondary sector

PHARM | 16


MD&D | 7

Circulation Concepts Inc.

PHARMA

MD&D | 12

STEALTH

MED DEVICES

CONSUMER

CONSUMER | 4

PHARMA | 5

Aether


20


Portfolio Companies by R&D Stages (PAGE 1 of 5)

PHARMA

MD

CONSUMER

Discovery (Research TI/TV)

Lead (H2L-LO)

Preclinical (GLP Tox-IND)

Phase 1

Phase 2a

Various

Not Applicable

62

39

34

15

18

5

15

Early Discovery

Early Development and Product Prototyping

Early Clinical and Product Development

Full Clinical and Product Development

Pre Revenue/ Commercial

7

30

21

3

7

Early Discovery

Early Development and Product Prototyping

Early Clinical and Product Development

Full Clinical and Product Development

Pre Revenue/ Commercial

8

10

9

12

8

21



62

Pharma | Discovery (Research, TI/TV)

39

Pharma | Lead (H2L-LO)

• STEALTH

• Distributed Bio

• NeuroTheryX

• Syng Pharma

• Ab Initio Biotherapeutics

• Locana Technologies

• 6Biotech

• Dragonfly Therapeutics

• Nucleo Life Sciences

• Synthex Labs

• Actavalon

• Meditope Biosciences, Inc.

• A2A Pharmaceuticals

• DTx Pharma

• Obsidian Therapeutics

• Tiaki Therapeutics

• Adicet Bio

• Navitor Pharmaceuticals, Inc.

• Abcombi Biosciences

• Envisagenics

• Perlstein Labs (aka Perlara)

• TREVENTIS Corporation

• Applied Molecular Transport

• Nexus Biopharma

• Advanced Proteome Therapeutics Corporation

• ExCellThera

• Persephone Biome

• STEALTH

• Atrapos (Fannin)

• Nkarta

• Glycomine

• Phenzyme

• Ubiquitech

• Avidity Biosciences

• Novoron

• STEALTH

• Golden Biotechnology Corp.

• Praedicare

• Winterlight Labs

• Bell Bio

• Oncternal Therapeutics

• Appili Therapeutics

• HealthBeacon

• Proteorex Therapeutics

• Wntrix Inc.

• Carna Biosciences

• Padlock Therapeutics

• Apricity

• IDA Therapeutics

• Qing Bile Therapeutics

• ZOETIC Pharmaceuticals

• CHIME BioTherapeutics

• PHusis Therapeutics

• Apros Therapeutics

• Ideaya Biosciences

• Ranomics

• Chimera Bioengineering

• Biosortia Pharmaceuticals

• Immune Biosolutions

• Realist Pharma

• Cible

• Pionyr Immunotherapeutics (fka Precision Immune)

• Biotagenics

• Kalgene Pharma Inc

• Courier Therapeutics

• STEALTH

• Cell Design Labs

• Ketogen

• Senti Biosciences (Exponential Genetics)

• Encoded Genomics

• Resonant Therapeutics, Inc.

• CERo Therapeutics

• STEALTH

• Siolta

• Endurx Pharmaceuticals, Inc.

• Riparian Pharma

• STEALTH

• Mannin Research

• SiteOne Therapeutics

• Forge Therapeutics

• Siragen Pharmaceuticals

• Chestnut Pharma

• Mediphage Bioceuticals

• Stelvio Oncology

• Immune Target

• Sirenas

• Compass Therapeutics (formerly Kairos Biologics)

• Mission Bio

• StemBioSys

• Immunobiochem Corporation

• SmartPhage

• Jecure Therapeutics

• Trianni

• Kymera Therapeutics (fka Project Chimera)

• Vanguard Therapeutics

• Cyclica • Cyteir Therapeutics • Deep Genomics

• Nanyang Technological University

• VLP Biotech • XTuit

22



34

Pharma | Preclinical (GLP Tox-IND)

18

Pharma | Phase 2a

• 4D Molecular Therapeutics

• EpiBiome

• Pimera

• Amarantus Therapeutics

• DNATrix

• Renascions

• Achelois Pharmaceuticals

• EpicentRx (fka AimRX)

• Poseida Therapeutics

• Amplyx Pharmaceuticals

• Iconic Therapeutics

• Sillajen Inc

• Agenovir

• Gene Sciences

• Quadriga

• Bellicum Pharmaceuticals

• Medicenna Therapeutics, Inc

• Symic Biomedical

• Alector

• Harpoon Tx

• Salarius Pharmaceuticals

• BlackThorn Therapeutics

• Mirati Therapeutics

• Triphase

• Arcturus Therapeutics

• Icell Kealex Therapeutics LLC

• Cidara

• Neurogeneration

• ViraCyte

• Audentes

• ImmunoMET Therapies

• Siamab Therapeutics (formerly Sialix)

• CURx Pharmaceuticals

• Neurolixis

• Vivozon Inc

• Batu Biologics

• Meissa Vaccines, Inc.

• Tizona Therapeutics

• Blade Therapeutics

• Vedanta Biosciences

• BlueRock Therapeutics

• Metaclipse Therapeutics Corporation

• Bridge Biotherapeutics Inc.

• OrPro Therapeutics

• Wellspring Biosciences

• Capella Therapeutics

• PanaMab Inc.

• Whole Biome

• Commence Bio (fka Wibi Works)

• Peptide Logic LLC

• Arsia Therapeutics

• Lectenz Bio (fka Glycosensors & Diagnostics)

• Phoenix Molecular Designs

• Cogniciti

• Nirmidas Biotech, Inc.

• Vitanova Biomedical

5

Pharma | Various • Amarantus Therapeutics

15

Pharma | Not Applicable Pharma | Phase 1

15

• Abilita Bio

• DNAstack

• Protocol Intelligence

• Afferent Pharma

• Beta Cat Pharmaceuticals LLC

• Ensysce Biosciences

• Animantis

• Linnaeus Bioscience

• Salgomed

• Annexon

• BioEclipse Therapeutics, Inc. (fka ConcentRx)

• Imago BioSciences

• Cellular Programming (fka Stemiotics)

• Misfolding Diagnostics

• Silicon Biosystems

• Molecular Assemblies

• StemoniX

• Cleo Life Sciences

• STEALTH

• Digital Proteomics

• Primordial Genetics

• Antiva Biosciences (fka Hera Therapeutics)

• Immunophotonics

• Celecor Therapeutics

• Medopad Buckingham Court

• Assembly

• Cortexyme

• OncoSynergy

• AvroBio

• Eidos Therapeutics

23



7

Medical Devices | Early Discovery

21

Medical Devices | Early Clinical and Product Development

• Atomo Diagnostics

• Glyscend INC

• RMIT University

• Acorn

• Enrich Biosciences

• NerveVision

• Control Panel, Inc (aka Droplet)

• Lin Bioscience

• Singular Genomics

• Barostitch

• Evaheart, Inc.

• NeuroSave

• Cam Med LLC

• Fibralign

• Noninvasix

• Clerio Vision

• LifeSprout, LLC

• PreDxion Bio, Inc

• Densitas

• MIMOSA Diagnostics

• PreventAGE Health Care

• Enable Biosciences Inc

• Miroculus

• Procyrion

• Endogena

• Nanovista Inc.

• Vax-Immune

• Nu Eyne Ltd

30

Medical Devices | Early Development and Product Prototyping • Adhesys Medical Inc

• Inpro Medical

• Allotrope Medical

• Intelligent Implants

• Pendant Biosciences (fka Nanoferix)

• Amydis

• Intheon (fka Syntrogi)

• Replete Biotics

• Analytics 4 Life

• IntuiTap

• Seegene Canada

• Ankasa

• Isommune

• Tracery Ophthalmics

• Cala Health

• App4 Independence

• STEALTH

• Translatum Medicus

• CureMatch

• Biodevek

• KODE Biotech Limited

• ViewPoint Therapeutics

• Cardiovate

• NAT Diagnostics

• STEALTH

• CorInnova, Inc.

• Notogen, Inc.

• DNA SEQ

• Omniome

• Glympse Bio • Green Sun Medical LLC • Inflammatix

Medical Devices | Full Clinical and Product Development

3

• Tiatros Inc.

Medical Devices | Pre Revenue/Commercial • Diomics Corporation

• Tem Systems

• Everist Health

• Third Pole Therapeutics

• KoruBio

• Yolia

7

• Nanomedical Systems

24



8

Consumer | Early Discovery • Astarte Medical Partners

• Biota Technology, Inc.

• Avicanna

• Boost Biomes (fka Coax Biosystems, Inc)

• Biocapital Holdings

12

Consumer | Full Clinical and Product Development

• CTX Technology (fka Actus Biotechnologies)

• CertaDose

• GPOWER

• Self Care Catalysts

• Correlia

• GraphWear Technologies

• Sienna Biopharmaceuticals

• Eikonic

• Dermala, Inc.

• Neutun

• Thesan Pharmaceuticals, Inc.

• STEALTH

• Eve Medical

• Portable Genomics

• Universal Diagnostics

10

Consumer | Early Development and Product Prototyping

8

Consumer | Pre Revenue/Commercial

• Aequor

• GlycosBio Food Sciences

• Patients We Share

• Aesela

• iDE8 Limited

• PinPress

• AOBiome LLC

• Ardra Bio

• Integra Medical

• Vapium

• Circulation Concepts Inc.

• Oncomfort

• CallMidwife.com

• Dosebiome (fka Appolonia Health)

• Cognuse

• eCubed Designs

• telmedx

• Seremedi, Inc.

9

Consumer | Early Clinical and Product Development • IGY Life Sciences Inc.

• Naked Biome

• Suncayr

• Lubris BioPharma LLC

• Neurotrack

• Xycrobe

• Mindera Corp

• Prapela • ProdermIQ

25


Portfolio Companies by Funding Stage (PAGE 1 of 4) Collectively, JLABS companies have secured greater than $9 billion through financings and strategic relationships. Search below to learn more about investments into the portfolio. 1

$1BN

18

$100MM – $50MM • Ensysce Biosciences

• Thesan Pharmaceuticals

• Sillajen Inc

• Poseida Therapeutics

• Annexon

• Neurogeneration

• Iconic Therapeutics

• Obsidian Therapeutics

• Padlock Therapeutics

• Tizona Therapeutics

• Navitor Pharmaceuticals, Inc.

• Cell Design Labs

• Symic Biomedical


• Afferent Pharma

• Pionyr Immunotherapeutics (fka Precision Immune)

• BlackThorn Therapeutics

• Harpoon Tx

• Adicet Bio

• Arcturus Therapeutics

3

$1BN – $500MM

$500MM – $100MM

10

• Vedanta Biosciences

• Cidara

• Alector

• Arsia Therapeutics

• BlueRock Therapeutics • Bellicum Pharmaceuticals

• Compass Therapeutics (formerly Kairos Biologics)

• Audentes

• Sienna Biopharmaceuticals

• Blade Therapeutics

• Omniome

• Amplyx Pharmaceuticals

26


Portfolio Companies by Funding Stage (PAGE 2 of 4) Collectively, JLABS companies have secured greater than $9 billion through financings and strategic relationships. Search below to learn more about investments into the portfolio. $50MM – $10MM

58

$10MM – $5MM

31

• DNATrix

• CorInnova, Inc.

• OncoSynergy

• 4D Molecular Therapeutics

• Nirmidas Biotech, Inc.

• Medopad Buckingham Court

• AOBiome LLC

• Cortexyme

• Sirenas

• Adhesys Medical Inc

• Cyteir Therapeutics

• Fibralign

• Ideaya Biosciences

• Singular Genomics

• Achelois Pharmaceuticals

• Biota Technology, Inc.

• Meditope Biosciences, Inc.

• Encoded Genomics

• Forge Therapeutics

• StemBioSys

• EpicentRx (fka AimRX)

• Lectenz Bio (fka Glycosensors & Diagnostics)

• KODE Biotech Limited

• CURx Pharmaceuticals

• NeuroSave

• STEALTH

• Cible

• Yolia

• Apros Therapeutics

• Molecular Assemblies

• Imago BioSciences • Applied Molecular Transport

• Atomo Diagnostics

• Antiva Biosciences (fka Hera Therapeutics)

• Salarius Pharmaceuticals

• Siamab Therapeutics (formerly Sialix)

• Cala Health

• ViraCyte

• Perlstein Labs (aka Perlara)

• Glympse Bio

• Metaclipse Therapeutics Corporation

• Analytics 4 Life

• Ankasa

• STEALTH

• Gene Sciences

• EpiBiome

• Siolta

• XTuit

• Whole Biome

• Everist Health

• Bell Bio

• Synthex Labs

• Dragonfly Therapeutics

• Beta Cat Pharmaceuticals LLC

• Glycomine

• Immunophotonics

• VLP Biotech

• Avidity Biosciences

• SiteOne Therapeutics

• Clerio Vision

• Icell Kealex Therapeutics LLC

• Kymera Therapeutics (fka Project Chimera)

• Evaheart, Inc.

• Agenovir

• Appili Therapeutics

• Mission Bio

• Carna Biosciences

• Procyrion

• Neurotrack

• Assembly

• Silicon Biosystems

• Lin Bioscience

• Advanced Proteome Therapeutics Corporation

• IGY Life Sciences Inc. • Oncternal Therapeutics • Eidos Therapeutics • Bridge Biotherapeutics Inc. • Golden Biotechnology Corp. • AvroBio • Jecure Therapeutics

• Medicenna Therapeutics, Inc

• StemoniX

• TREVENTIS Corporation

• Tem Systems

• Deep Genomics • Biosortia Pharmaceuticals

• STEALTH • ImmunoMET Therapies

• Third Pole Therapeutics

27


Portfolio Companies by Funding Stage (PAGE 3 of 4) Collectively, JLABS companies have secured greater than $9 billion through financings and strategic relationships. Search below to learn more about investments into the portfolio. $5MM – $2.5MM

35

$2.5MM – $1MM

50

• STEALTH

• Actavalon

• Intheon (fka Syntrogi)

• Isommune

• telmedx

• ProdermIQ

• Distributed Bio

• Cogniciti

• Amydis

• Noninvasix

• Cam Med LLC

• Portable Genomics

• Lubris BioPharma LLC

• OrPro Therapeutics

• PHusis Therapeutics

• Digital Proteomics

• PreventAGE Health Care

• Naked Biome

• Dosebiome (fka Appolonia Health)

• Notogen

• CureMatch

• Siragen Pharmaceuticals

• Green Sun Medical LLC

• Universal Diagnostics

• STEALTH

• Prapela

• Envisagenics

• Endurx Pharmaceuticals, Inc.

• BioDevek

• Nanomedical Systems

• Chimera Bioengineering

• Vanguard Therapeutics

• Kalgene Pharma Inc

• Vax-Immune

• Novoron

• STEALTH

• Cleo Life Sciences

• Qing Bile Therapeutics

• Densitas

• Eve Medical

• STEALTH

• Seremedi, Inc.

• Abilita Bio

• Aequor

• Batu Biologics

• Pendant Biosciences (fka Nanoferix)

• Avicanna

• Trianni

• Pimera

• Primordial Genetics

• Capella Therapeutics

• Ranomics

• Tiaki Therapeutics

• Resonant Therapeutics, Inc.

• CERo Therapeutics

• STEALTH

• Immune Biosolutions

• Vivozon Inc

• Riparian Pharma

• NAT Diagnostics

• Tiatros Inc.

• Integra Medical

• GlycosBio Food Sciences

• Self Care Catalysts

• NerveVision

• LifeSprout, LLC

• Animantis

• Diomics Corporation

• Ketogen

• ExCellThera

• Wntrix Inc.

• Suncayr

• Meissa Vaccines, Inc.

• Immune Target

• BioEclipse Therapeutics, Inc. (fka ConcentRx)

• Phoenix Molecular Designs

• PanaMab Inc.

• ViewPoint Therapeutics • Cyclica

• Quadriga

• Control Panel, Inc (aka Droplet)

• Aesela

• Translatum Medicus

• Nkarta • Peptide Logic LLC

28


Portfolio Companies by Funding Stage (PAGE 4 of 4) Collectively, JLABS companies have secured greater than $9 billion through financings and strategic relationships. Search below to learn more about investments into the portfolio. $1MM – $250K

48

49

< $250K

• Cardiovate

• GPOWER

• Allotrope Medical

• Patients We Share

• Eikonic

• Chestnut Pharma

• DNA SEQ

• Cognuse

• Stelvio Oncology

• Nu Eyne Ltd

• Endogena

• Inflammatix

• Linnaeus Bioscience

• Commence Bio (fka Wibi Works)

• Phenzyme

• SmartPhage

• Inpro medical

• Oncomfort

• Triphase

• Abcombi Biosciences

• Astarte Medical Partners

• Koru Bio

• Winterlight Labs

• Mediphage Bioceuticals

• Nanovista Inc.

• CallMidwife.com

• Locana Technologies

• Immunobiochem Corporation

• 6Biotech

• Enrich Biosciences

• Tracery Ophthalmics

• Mannin Research

• Wellspring Biosciences

• Atrapos (Fannin)

• Ardra Bio

• Neutun

• Vapium

• Mirati Therapeutics

• RMIT University

• Enable Biosciences Inc

• PinPress

• Misfolding Diagnostics

• A2A Pharmaceuticals

• Praedicare

• Xycrobe

• GraphWear Technologies


• Replete Biotics

• Protocol Intelligence

• Glyscend INC

• DTx Pharma

• Syng Pharma

• iDE8 Limited

• Renascions

• Salgomed

• Proteorex Therapeutics

• Acorn

• Barostitch

• Seegene Canada

• Dermala, Inc.

• IDA Therapeutics

• Biotagenics

• Ab Initio Biotherapeutics

• Intelligent Implants

• Persephone Biome

• CertaDose

• App4 Independence

• Senti Biosciences (Exponential Genetics)

• MirOculus

• Neurolixis

• Nucleo Life Sciences

• Biocapital Holdings

• Ubiquitech

• DNAstack

• CHIME BioTherapeutics

• STEALTH

• ZOETIC Pharmaceuticals

• NeuroTheryX

• Circulation Concepts Inc.

• Vitanova Biomedical

• Boost Biomes (fka Coax Biosystems, Inc)

• Correlia

• Courier Therapeutics

• HealthBeacon

• Celecor Therapeutics

• Apricity

• Realist Pharma

• CTX Technology (fka Actus Biotechnologies)

• Nanyang Technological University

• Cellular Programming (fka Stemiotics)

• IntuiTap

• PreDxion Bio, Inc

• MIMOSA Diagnostics

• eCubed Designs

• STEALTH

• Mindera Corp • Nexus Biopharma

29

QuickFire Challenges

30


JLABS QuickFire Challenges (PAGE 1 of 7) QuickFire Challenge winning companies: 46 Providing a platform for the scientific community to apply diverse perspectives to solving healthcare challenges. Our vision is to unleash the competitive spirit of the innovation ecosystem to create healthcare solutions in unconventional ways. We inspire the best in science and technology by providing real world challenges and granting a variety of awards. Click a challenge below for more information

DIGITAL BEAUTY

THE LABCOAT OF THE FUTURE

PATIENT ADHERENCE

ARTIFICIAL INTELIGENCE FOR DRUG DISCOVERY

SEOUL INNOVATION

SINGAPORE METABOLIC DISEASE INNOVATION

BUGS, DRUGS & BEYOND (TMC)

JLABS @ M2D2

LATIN AMERICA

JLABS SAN DIEGO

JLABS @ NYC

NEXT-GEN BABY BOX

BUGS, DRUGS & BEYOND (Bay Area & Boston)

CDI @ TMC

ADVANCING THE SAFE USE OF HEALTHCARE

NEXT-GEN SUPPLY CHAIN

WORLD WITHOUT DISEASE

JLABS @ TORONTO

JLABS @ TMC

ADVANCE QUEENSLAND JOHNSON & JOHNSON INNOVATION

JLABS @ SSF

JLABS @ LABCENTRAL

31


JLABS QuickFire Challenges (PAGE 2 of 7)

THE LABCOAT OF THE FUTURE

JLABS @ NYC

DIGITAL BEAUTY

In honor of the 5-year anniversary of the first Johnson & Johnson Innovation, JLABS site, JLABS launched the San Diego QuickFire Challenge in 2017 to award a cutting edge, early-stage innovation company $25,000 in grants, residency and access to the JLABS San Diego community for one year.

In honor of the of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation launched the JLABS @ NYC QuickFire Challenge in 2017 to award up to four new game-changing early-stage innovation companies with residency and access to the JLABS @ NYC community for one year.

Johnson & Johnson Innovation, JLABS and Johnson & Johnson Consumer Inc. launched the Digital Beauty QuickFire Challenge in 2017 to award new, gamechanging digital beauty innovations with up to $50,000 in grant funding, potential residency at an available local JLABS, access to a network of consumer experts, and admission to test the product with consumers at the Johnson & Johnson Consumer Inc. Consumer Experience Center (CxC).

Johnson & Johnson Innovation launched The LabCoat of the Future Challenge, the first in the Champions of Science “What’s New?” QuickFire Challenge series, launched in 2017 to award new innovations related to the traditional lab coat in the areas of: construct/shape/ design, composition/materials and the incorporation of new solutions (i.e., wearable technologies). The winning solution will be awarded $50,000 in grant funding, mentorship and the potential to test the new lab coat design at JLABS.

Residency at JLABS San Diego and $25,000

Residency at JLABS @ NYC

$50,000

$50,000

FOCUS AREAS: • Consumer healthcare • Health technologies • Medical devices • Therapeutics

FOCUS AREAS: • Insights-Generating Tools • Impact Tracking Devices and Adherence Solutions • Digital Technologies or Devices

FOCUS AREAS: • Construct/Shape/Design • Composition/Materials • Incorporation of new solutions (i.e., wearable technologies)

INCLUDED: • Residency • Mentoring

INCLUDED: • Funding (Up to $50,000 USD) • Mentoring • Residency

INCLUDED: • Funding (grant funds) • Mentoring

JLABS SAN DIEGO

FOCUS AREAS: • Consumer Devices • Global Public Health • Health technologies • Medical devices • Therapeutics INCLUDED: • Funding (grant funds) • Mentoring • Residency

32


JLABS QuickFire Challenges (PAGE 3 of 7) PATIENT ADHERENCE

ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY

SEOUL INNOVATION

NEXT-GEN BABY BOX

Johnson & Johnson Innovation, JLABS and Janssen Supply Group, LLC launched the Patient Adherence QuickFire Challenge in 2017 to award a company developing new solutions focused on transforming the customer experience by improving patient outcomes through patient engagement, adherence, and tailored care $75,000 in grant funding and mentorship.

Johnson & Johnson Innovation, JLABS and Janssen Research & Development launched the Artificial Intelligence for Drug Discovery QuickFire Challenge in 2017 to award new, game-changing artificial intelligence related innovations up to $100,000 in grant funding, residency and access to the JLABS community and mentorship.

Johnson & Johnson Innovation, JLABS in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI), Janssen Korea Ltd. and Johnson & Johnson Medical Korea Ltd. launched the Seoul Innovation QuickFire Challenge in 2017 to award two global game-changing, early-stage innovations addressing a health need for the world’s population a total of KRW 150,000,000 (approximately US$134,000) in grant funding, entrance to the Seoul Bio Hub, and mentorship.

Johnson & Johnson Innovation, JLABS and Janssen Research & Development launched the Next-Gen Baby Box QuickFire Challenge in 2017 to award new, gamechanging innovations or ideas in the areas promoting child health, detecting childhood illness and disease and facilitating parenting up to $350,000 in grant funding, mentorship, and the opportunity to pilot their solution in Finland.

$75,000

$100,000

150,000,000 KRW

$350,000

INCLUDED: • Funding – Grant Funds • Mentoring

FOCUS AREAS:

FOCUS AREAS: • Health Technologies • Medical Devices • Therapeutics

FOCUS AREAS: • Promoting Child Health • Detecting Childhood Illness and Disease • Facilitating Parenting

INCLUDED: • Funding (KRW) • Mentoring • Residency

INCLUDED: • Funding (Up to $350,000 USD) • Mentoring

WINNER:

PRIZE AWARDED

• Oncology & Immuno-oncology • Immunology • Cardiovascular & Metabolism • Infectious Diseases & Vaccines • Neuroscience • Pulmonary Hypertension • Rare Diseases • Pre-clinical safety studies • Systems pharmacology • Clinical trials • Precision Medicine • Chemo-informatics • In silico compound & safety profiling • Real world evidence

INCLUDED: • Funding (rewards & benefits) • Mentoring • Residency

WINNERS:

WINNERS:

WINNERS:

PRIZE AWARDED

PRIZE AWARDED

PRIZE AWARDED

33


JLABS QuickFire Challenges (PAGE 4 of 7) BUGS, DRUGS & BEYOND (Bay Area & Boston)

ADVANCING THE SAFE USE OF HEALTHCARE

CDI @ TMC

SINGAPORE METABOLIC DISEASE INNOVATION

Johnson & Johnson Innovation, JLABS and the Janssen Human Microbiome Institute launched the second Bugs, Drugs, & Beyond QuickFire Challenge in 2017 to award two new, game-changing, early-stage microbiome companies with a total of $75,000 in grant funding or residency and access to the JLABS @ South San Francisco or JLABS @ LabCentral communities.

In conjunction with the Grand Opening of the Center for Device Innovation (CDI @ TMC) in 2017, Johnson & Johnson Innovation and Johnson & Johnson Medical Devices launched the CDI @ TMC QuickFire Challenge to award three game-changing early-stage medical device innovations up to $350,000 in grant funding and potential investment from AngelMD and, for the grand prize winner, residency and access to the JLABS @ TMC community for one year.

Johnson & Johnson Innovation and the Johnson & Johnson Office of the Chief Medical Officer launched the Advancing the Safe Use of Healthcare QuickFire Challenge in 2017 to award new, innovative solutions on how to educate, inform and provide clarity around healthcare product safety up to $200,000 in grant funding and residency and access to the JLABS community for one year.

Johnson & Johnson Innovation, JLABS in collaboration with Exploit Technologies Pte Ltd (ETPL) and Singapore-MIT Alliance for Research and Technology (SMART), launched the Singapore QuickFire Challenge – Metabolic Disease Innovation in 2017 to award three game-changing, early-stage innovations that address critical health concerns related to metabolic diseases such as diabetes and obesity a total of $300,000 SGD in project money.

$75,000

$400,000

$200,000

$100,000 SGD

FOCUS AREAS: • Consumer healthcare • Digital healthcare • Medical devices • Pharmaceutical

FOCUS AREAS: • Cardiovascular • Obesity • Osteoarthritis • Surgical Oncology

FOCUS AREAS: • Consumer healthcare • Health technologies • Surgery

FOCUS AREAS: • Consumer healthcare • Diagnostics Health technologies • Medical Devices • Therapeutics



WINNERS:

WINNERS:

PRIZE AWARDED


INCLUDED: • Funding (Up to $100,000 SGD) • Mentoring

WINNER:

WINNERS:

PRIZE AWARDED

PRIZE AWARDED

PRIZE AWARDED

34


JLABS QuickFire Challenges (PAGE 5 of 7) BUGS, DRUGS & BEYOND (TMC)

JLABS @ M2D2

NEXT-GEN SUPPLY CHAIN

Johnson & Johnson Innovation, JLABS and Janssen Human Microbiome Institute launched the Bugs, Drugs and Beyond QuickFire Challenge in 2017 to award a new, game-changing, early-stage microbiome company with residency and access to JLABS @ TMC for one year.

In conjunction with the Grand Opening of JLABS @ M2D2, Johnson & Johnson Innovation, JLABS launched a QuickFire Challenge in 2016 to award a new gamechanging early-stage innovation company with residency and access to the JLABS @ M2D2 community for one year.

Johnson & Johnson Innovation, JLABS and Janssen Supply Chain Group launched the Next-Gen Supply Chain QuickFire Challenge in 2016 to identify new, innovative solutions to common manufacturing and supply chain challenges and award the winning solution with $75,000 in grant funding and mentorship.

Johnson & Johnson Innovation, JLABS and Janssen Research & Development launched the World Without Disease QuickFire Challenge in 2016 to award $1.5M grant funding to new game-changing companies that are developing solutions to improve the health and wellness of people around the world by deploying comprehensive, end-to-end, integrated solutions that take into account the world in which we live today.

Residency at JLABS

Residency

$75,000

$1,500,000 + Residency

FOCUS AREAS: • Consumer healthcare • Health technologies • Microbiome • Therapeutics

FOCUS AREAS: • Cardiovascular • Diabetes • Neurovascular • Orthopedics • Surgery • Vision care

FOCUS AREAS: • Medical Devices

FOCUS AREAS: • Consumer healthcare • Medical Devices • Therapeutics


INCLUDED: • Funding (grant funds) • Mentoring

INCLUDED: • Funding • Residency • Mentoring

WINNER:


WINNER:

WORLD WITHOUT DISEASE

WINNERS:

STEALTH

WINNER: PRIZE AWARDED

PRIZE AWARDED

PRIZE AWARDED

PRIZE AWARDED

35


JLABS QuickFire Challenges (PAGE 6 of 7)

ADVANCE QUEENSLAND JOHNSON & JOHNSON INNOVATION

JLABS @ TORONTO

JLABS @ TMC

LATIN AMERICA

In conjunction with the Grand Opening of JLABS @ Toronto, Johnson & Johnson Innovation, JLABS launched a QuickFire Challenge to award new gamechanging early-stage innovation companies residency and access to the JLABS @ Toronto community for one year. In addition, all winners received memberships from BIOTECANADA and OBIO, and the Medical Device winners received a membership from Medec.

In conjunction with the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation, JLABS launched a QuickFire Challenge in 2015 to award up to four new game-changing early-stage innovation companies residency and access to the JLABS @ TMC community for one year.

As part of the innovation forum for Latin America, Johnson & Johnson Innovation, JLABS committed to award one new game-changing early-stage innovation company from Latin America residency and access to the JLABS @ TMC community for six months through participation in a QuickFire Challenge.

The Queensland State Government in collaboration with Johnson & Johnson Innovation, JLABS launched the Advance Queensland Johnson & Johnson Innovation QuickFire Challenge in 2015 to award up to three new game-changing early-stage human healthcare inventions with an a total of AUD 300,000 in grant funding and access to mentorship and coaching from J&J.

Residency at JLABS

Residency at JLABS

Residency at JLABS

$100,000 AUS

FOCUS AREAS: • Consumer Healthcare • Health technologies • Medical devices • Therapeutics

FOCUS AREAS: • Consumer healthcare • Medical devices • Therapeutics

FOCUS AREAS: • Therapeutics

FOCUS AREAS: • Consumer healthcare • Medical devices • Therapeutics




INCLUDED: • Funding (up to AUS $100,000) • Mentoring

WINNER:

WINNERS:

WINNERS:

WINNERS:

PRIZE AWARDED

PRIZE AWARDED

PRIZE AWARDED

PRIZE AWARDED

36


JLABS QuickFire Challenges (PAGE 7 of 7) JLABS @ SSF

JLABS @ LABCENTRAL

In conjunction with the Grand Opening of JLABS @ South San Francisco in 2015, Johnson & Johnson Innovation, JLABS launched a QuickFire challenge to award up to three new game-changing early-stage innovation companies with residency and access to the JLABS @ South San Francisco community for one year.

In conjunction with the Grand Opening of JLABS @ LabCentral in 2014, Johnson & Johnson Innovation launched a QuickFire Challenge to award new gamechanging early-stage innovation companies with residency and access to the JLABS @ LabCentral community for one year.

Residency at JLABS

Residency at JLABS





WINNERS:

WINNERS:

PRIZE AWARDED

PRIZE AWARDED

37

Keep in Touch!


Interested in learning more about JLABS? Visit jlabs.jnjinnovation.com and register here for the latest news, events and information.

38

39